

**AMENDMENTS TO THE CLAIMS**

1.-2. (Cancelled)

3. **(Previously presented)** A method of treating diabetes and/or microvascular diabetic complications comprising administering C-peptide or a pharmaceutical composition comprising C-peptide to a patient in a once daily dose, wherein said once daily dose does not include a continuous administration or the presence of release rate-controlling agents.

4.-9. (Canceled)

10. **(Previously presented)** The method according to Claim 3, wherein the C-peptide is human C-peptide

11. **(Previously presented)** The method according to Claim 3, wherein said C-peptide is a fragment EGSLQ (SEQ ID NO: 2).

12. **(Previously presented)** The method according to Claim 3, wherein the patient is a human.

13. **(Previously presented)** The method according to Claim 3, wherein the medicament contains 100 to 1800 nmol of C- peptide.

14. **(Previously presented)** The method according to Claim 3, wherein the medicament is an uncompromised aqueous solution.

15. **(Previously presented)** The method according to Claim 3, wherein said complications are diabetic nephropathy, retinopathy or neuropathy.